Leading biopharmaceutical company Bristol-Myers Squibb (BMY) reported solid financials in the last quarter. Its diversified product portfolio and inelastic demand for such products brighten its near-term prospects. Moreover, the company’s…
© 2023 The Abundance Pub. All rights reserved.
All trademarks and service marks are the property of their respective owners. This site is not intended to provide, and does not constitute, medical, health, legal, investment, financial or other professional advice.